ProCE Banner Activity

FAQs: Role of Immunotherapy in Biliary Tract Cancer

Clinical Thought

In this commentary, I address frequently asked questions on the current and emerging roles of immune checkpoint inhibitors in the management of patients with biliary tract cancer based on the latest available evidence.

Released: December 18, 2024

Expiration: June 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Disclosure

Program Director

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP: researcher (paid to institution): Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Seattle Genetics; consultant (paid to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck, Merck KGaA, Merus, Pfizer, Seattle Genetics, Servier; consultant: AbbVie, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Elevar, Exact Science, Exelixis, Foundation Medicine, GlaxoSmithKline, Illumina, Janssen, Kanaph, Natera, Sanofi, Sobi, Stemline, TreosBio, Xilio, Zai Labs; data and safety monitoring board: 1Globe, AstraZeneca, Exelixis, Fibrogen, Merck/Eisai, Suzhou Kintor; advisor: Artiva, Imugene, Immuneering, Replimune, Sun Biopharma, Xilis.

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Lipika Goyal, MD, MPhil: researcher: Alyssum Therapeutics, Boehringer Ingelheim, Genentech; consultant: AbbVie, Agenus, Boehringer Ingelheim, Compass Therapeutics, Exelixis, Kinnate Biopharma, Merck, Relay Therapeutics, Servier, Surface Oncology, Taiho, TransThera Biosciences, Tyra Biosciences; data and safety monitoring board: AstraZeneca.

Primary Author

Richard Kim, MD

Service Chief of GI Oncology
Professor
Moffitt Cancer Center
Tampa, Florida

Richard Kim, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Eisai, Exelixis, Incyte, Jazz, Roche, Taiho, Takeda.